본문 바로가기
KERD
논문KCI 등재

Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group

김인호|김지현|김진원|김지훈|김승태|김미소|정재호|이인희|안희경|유창훈|김태원|박인근|김한상|홍용상|장세진|윤홍석|강진형|차용준|장대영|윤지나|임선민|천재경|김효송|윤신교
대한암학회 (Korean Cancer Association)|2022.01|Cancer Research and Treatment|제54권 제1호|pp. 1-9|DOI 10.4143/crt.2021.1115

2

조회

0

다운로드

6

인용

0

참고문헌

키워드

Next-generation sequencingPrecision medicineMolecular tumor boardAdvanced solid cancerGenomic alterations
주제분류의학일반

초록

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

Abstract

Next-generation sequencing (NGS) is becoming essential in the fields of precision oncology. With implementation of NGS in daily clinic, the needs for continued education, facilitated interpretation of NGS results and optimal treatment delivery based on NGS results have been addressed. Molecular tumor board (MTB) is multidisciplinary approach to keep pace with the growing knowledge of complex molecular alterations in patients with advanced solid cancer. Although guidelines for NGS use and MTB have been developed in western countries, there is limitation for reflection of Korea's public health environment and daily clinical practice. These recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.

참고문헌 (40)

  1. Collins FS, "A new initiative on precision medicine", N Engl J Med, 372, pp.793~795 (2015)
  2. Biankin AV, "Patient-centric trials for therapeutic development in precision oncology", Nature, 526, pp.361~370 (2015)
  3. Zehir A, "Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10, 000 patients", Nat Med, 23, pp.703~713 (2017)
  4. Marino P, "Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice : a nationwide French study", Eur J Hum Genet, 26, pp.314~323 (2018)
  5. Tobin NP, "The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer", J Intern Med, 278, pp.545~570 (2015)
  6. 이세훈, "Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients", Cancer Research and Treatment, 51(1), pp.211~222 (2019), 대한암학회
  7. Grellety T, "High-depth sequencing of paired primary and metastatic tumours : implications for personalised medicine", Eur J Cancer, 84, pp.250~256 (2017)
  8. Manca A, "Mutational concordance between primary and metastatic melanoma : a next-generation sequencing approach", J Transl Med, 17, pp.289~ (2019)
  9. Crumley SM, "Next-generation sequencing of matched primary and metastatic rectal adenocarcinomas demonstrates minimal mutation gain and concordance to colonic adenocarcinomas", Arch Pathol Lab Med, 140, pp.529~535 (2016)
  10. McGranahan N, "Biological and therapeutic impact of intratumor heterogeneity in cancer evolution", Cancer Cell, 27, pp.15~26 (2015)
  11. Cho M, "Tissue recommendations for precision cancer therapy using next generation sequencing : a comprehensive single cancer center’s experiences", Oncotarget, 8, pp.42478~42486 (2017)
  12. Carithers LJ, "The biospecimen preanalytical variables program : a multiassay comparison of effects of delay to fixation and fixation duration on nucleic acid quality", Arch Pathol Lab Med, 143, pp.1106~1118 (2019)
  13. Chen G, "Cytosine deamination is a major cause of baseline noise in next-generation sequencing", Mol Diagn Ther, 18, pp.587~593 (2014)
  14. Kim S, "Deamination effects in formalin-fixed, paraffin-embedded tissue samples in the era of precision medicine", J Mol Diagn, 19, pp.137~146 (2017)
  15. Ignatiadis M, "Liquid biopsy enters the clinic : implementation issues and future challenges", Nat Rev Clin Oncol, 18, pp.297~312 (2021)
  16. Mateo J, "A framework to rank genomic alterations as targets for cancer precision medicine : the ESMO Scale for Clinical Actionability of molecular Targets(ESCAT)", Ann Oncol, 29, pp.1895~1902 (2018)
  17. Chakravarty D, "OncoKB: a precision oncology knowledge base", JCO Precis Oncol, 2017, pp.PO.17.0001~ (2017)
  18. Jennings LJ, "Guidelines for validation of next-generation sequencing-based oncology panels : a joint consensus recommendation of the Association for Molecular Pathology and College of American Pathologists", J Mol Diagn, 19, pp.341~365 (2017)
  19. Heydt C, "Detection of gene fusions using targeted next-generation sequencing : a comparative evaluation", BMC Med Genomics, 14, pp.62~ (2021)
  20. Strickler JH, "Tumor mutational burden as a predictor of immunotherapy response : is more always better?", Clin Cancer Res, 27, pp.1236~1241 (2021)
  21. Marabelle A, "Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab : prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study", Lancet Oncol, 21, pp.1353~1365 (2020)
  22. Fancello L, "Tumor mutational burden quantification from targeted gene panels : major advancements and challenges", J Immunother Cancer, 7, pp.183~ (2019)
  23. Le DT, "Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade", Science, 357, pp.409~413 (2017)
  24. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
  25. Luchini C, "ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1", PD-L1 expression and tumour mutational burden : a systematic review-based approach, 2019, pp.30, 1232~1243
  26. Dedeurwaerdere F, "Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer", Sci Rep, 11, pp.12880~ (2021)
  27. Luchini C, "Molecular tumor boards in clinical practice", Trends Cancer, 6, pp.738~744 (2020)
  28. van der Velden DL, "Molecular tumor boards : current practice and future needs", Ann Oncol, 28, pp.3070~3075 (2017)
  29. Larson KL, "Clinical outcomes of molecular tumor boards: a systematic review", JCO Precis Oncol, 5, pp.PO.20.0049~ (2021)
  30. Pishvaian MJ, "A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients", JAMIA Open, 2, pp.505~515 (2019)
  31. Rao S, "Collaborative, multidisciplinary evaluation of cancer variants through virtual molecular tumor boards informs local clinical practices", JCO Clin Cancer Inform, 4, pp.602~613 (2020)
  32. "Process for off-label drug use for chemotherapy" (2018)[URL]
  33. "Guideline for expanded access program" (2020)[URL]
  34. Walsh S, "Decision support systems in oncology", JCO Clin Cancer Inform, 3, pp.1~9 (2019)
  35. Blasi L, "Virtual clinical and precision medicine tumor boards-cloud-based platform-mediated implementation of multidisciplinary reviews among oncology centers in the COVID-19 era : protocol for an observational study", JMIR Res Protoc, 10, pp.e26220~ (2021)
  36. Kato S, "Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy", Nat Commun, 11, pp.4965~ (2020)
  37. 최윤지, "Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations", Cancer Research and Treatment, 54(1), pp.30~39 (2022), 대한암학회[DOI]
  38. Nakamura Y, "SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN : path to the realization of biomarker-guided precision oncology in advanced solid tumors", Cancer Sci, 112, pp.4425~4432 (2021)
  39. Barlesi F, "Routine molecular profiling of patients with advanced non-small-cell lung cancer : results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup(IFCT)", Lancet, 387, pp.1415~1426 (2016)
  40. 이영우, "Clinical Application of Targeted Deep Sequencing in Metastatic Colorectal Cancer Patients: Actionable Genomic Alteration in K-MASTER project", Cancer Research and Treatment, 53(1), pp.123~130 (2021), 대한암학회[DOI]

관련 논문AI추천

분자종양위원회의 임상적 실제이수현대한내과학회 · 대한내과학회지2022 · 제97권 제5호Clinical Practice Recommendations for the Use of Next-Generation Sequencing in Patients with Solid Cancer: A Joint Report from KSMO and KSP김미소, 김시현, 김완섭, 김인호, 김지현, 김지형, 김지훈, 김진원, 김한상, 김한조, 김형돈, 나기용, 남수정, 박세훈, 박소연, 박인근, 심효섭, 유창훈, 윤선옥, 윤신교, 윤진아, 윤홍석, 이성영, 이아원, 이인희, 이지은, 이충근, 이혜승, 임선민, 장기택, 전상훈, 정재호, 정현애, 조영미, 차용준, 천재경, 홍숙희대한암학회 · Cancer Research and Treatment2024 · 제56권 제3호Clinical practice recommendations for the use of next-generation sequencing in patients with solid cancer: a joint report from KSMO and KSP김미소, 김시현, 김완섭, 김인호, 김지현, 김지형, 김지훈, 김진원, 김한상, 김한조, 김형돈, 나기용, 남수정, 박세훈, 박소연, 박인근, 심효섭, 윤선옥, 윤신교, 윤지나, 윤홍석, 이성영, 이아원, 이인희, 이지은, 이충근, 이혜승, 임선민, 장기택, 전상훈, 정재호, 정현애, 조영미, 차용준, 천재경, 홍숙희, Changhoon Yoo대한병리학회 · Journal of Pathology and Translational Medicine2024 · 제58권 제4호Erratum : Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group강진형, 김미소, 김승태, 김인호, 김지현, 김지훈, 김진원, 김태원, 김한상, 김효송, 박인근, 안희경, 유창훈, 윤신교, 윤지나, 윤홍석, 이인희, 임선민, 장대영, 장세진, 정재호, 차용준, 천재경, 홍용상대한암학회 · Cancer Research and Treatment2023 · 제55권 제3호Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients강진형, 고영혜, 김상겸, 김숙영, 김열홍, 김종일, 김지훈, 김철민, 김태원, 김태유, 김형래, 노동영, 라선영, 문형곤, 박근칠, 박웅양, 심준호, 유창식, 유한석, 윤재원, 이광우, 이보람, 이세훈, 이재련, 임석아, 정경해, 정연준, 정현철, 조석기, 하상윤대한암학회 · Cancer Research and Treatment2019 · 제51권 제1호Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations강은주, 김열홍, 김영생, 김유정, 김정선, 김주원, 김혜숙, 박경화, 박지현, 성재숙, 신상원, 안미선, 이수현, 이영우, 이종원, 임승택, 임아름, 임태규, 장원진, 정희준, 조성심, 조장호, 최윤지, 최정윤대한암학회 · Cancer Research and Treatment2022 · 제54권 제1호

이 간행물의 다른 논문 (29건)

Validation of the Korean Version of the Patient-Reported Outcomes Measurement Information System 29 Profile V2.1 among Cancer Survivors윤정희, 임지현, 조주희, 남희수, 이만경, 복혜숙, 이상원, 김수연, 강은지, 안진석, 오동렬, 신수용, 김영하, 강단비, 심성근pp. 10-19Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea김달용, Dae Seog Heo, 임채만, 유신혜, 신성준, 김도연, Min Sun Kim, 이현정, 서세영, 임지연pp. 20-29Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations신상원, 임승택, 장원진, 박경화, 이종원, 강은주, 조성심, 김정선, 임태규, 김혜숙, 김유정, 이수현, 최정윤, 김주원, 조장호, 안미선, 임아름, 김영생, 박지현, 이영우, 정희준, 김열홍, 최윤지, 성재숙pp. 30-39Targeted Liquid Biopsy Using Irradiation to Facilitate the Release of Cell-Free DNA from a Spatially Aimed Tumor Tissue박지현, 안원균, 노재명, 표홍렬, 박웅양, 이호연, 김연정, 최창훈, 이태섭, 박동현pp. 40-53Increased Radiosensitivity of Solid Tumors Harboring ATM and BRCA1/2 Mutations이준복, 김한상, 윤홍인, 장지석, 양지훈, 김경환, 안중배, 심효섭, 김승섭pp. 54-64
원문 보기